Physician profile
John Michael Moore
NPI 1902154172
$21,013.87
in general payments reported to CMS, 2019-2025
41 companies · $67.97 in 2025
The $67.97 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,270 · 2022: $1,538 · 2023: $11K · 2024: $5,814 · 2025: $67.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $2,896 · Travel and Lodging: $2,117 · Entertainment: $42.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,150.00 |
| Food and Beverage | $2,896.25 |
| Travel and Lodging | $2,116.99 |
| Entertainment | $42.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16,246.11 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $964.91 | 2021 | |
| Amgen INC. | $802.96 | 2021-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $351.58 | 2021-2024 | Farxiga, Breztri |
| Lilly USA, LLC | $331.89 | 2021-2024 | Mounjaro, Trulicity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $283.55 | 2022-2024 | Caplyta |
| Viiv Healthcare Company | $229.30 | 2023-2024 | Apretude |
| Janssen Pharmaceuticals, INC | $205.63 | 2021-2024 | Spravato |
| Nestle Healthcare Nutrition INC. | $152.96 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $139.75 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $116.69 | 2021-2024 | Livalo |
| Phathom Pharmaceuticals, INC. | $83.44 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $83.06 | 2023 | |
| Idorsia Pharmaceuticals US INC | $81.15 | 2023 | Quviviq |
| Abbott Laboratories | $80.54 | 2021-2023 | Freestyle Libre 2 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.